INTRODUCTION
• Large RCTs have major contribution in scientific advances and provide the most reliable evidence for clinical practice
• Despite this, majority of clinical guidelines are still based on non-randomised observational data, surrogate outcome trials and expert consensus
• We evaluated all abstracts of studies presented at ESC Congress 2015 for clinical, randomised studies and their primary endpoints, power and positivity.
METHODS
• All published abstracts of ESC Congress 2015 were reviewed
• Abstracts classified as basic science or clinical
• Clinical abstracts as observational, randomised studies or meta-analysis 
DISCUSSION
• ESC Congress 2015 only 4% of abstracts were randomised trials, and 0.25% had primary clinical endpoint with adequately power >80%
• Furthermore, underpowered clinical endpoint and surrogate outcome studies more likely to be positive, paradoxically
• Already one of the largest international conference where major trials presented; even less "qualified" randomised trials at smaller conferences
DISCUSSION -CHALLENGES
• Small number of large clinical RCT reflect cost and logistical challenges
• Many large trials funded by industry
• Large trials can still have flaws
• Underpowered studies can be misleading when positive or negative
• There is need for simpler and novel study designs
